These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25527213)

  • 1. Is there an association between the coverage of immunisation boosters by the age of 5 and deprivation? An ecological study.
    Sandford H; Tata LJ; Browne I; Pritchard C
    Vaccine; 2015 Feb; 33(9):1218-22. PubMed ID: 25527213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
    Black S; Friedland LR; Schuind A; Howe B;
    Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections.
    Sørup S; Benn CS; Poulsen A; Krause TG; Aaby P; Ravn H
    JAMA; 2014 Feb; 311(8):826-35. PubMed ID: 24570246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
    Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
    Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration.
    MMR-158 Study Group
    Hum Vaccin Immunother; 2019; 15(4):786-799. PubMed ID: 30785357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.
    Marshall H; Nolan T; Roberton D; Richmond P; Lambert S; Jacquet JM; Schuerman L
    Vaccine; 2006 Aug; 24(35-36):6120-8. PubMed ID: 16822597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children.
    Kemmeren JM; Timmer SS; van der Maas NA; de Melker HE
    Vaccine; 2011 Jun; 29(26):4373-7. PubMed ID: 21514347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timeliness and completeness of routine childhood vaccinations in young children residing in a district with recurrent vaccine-preventable disease outbreaks, Jerusalem, Israel.
    Stein-Zamir C; Israeli A
    Euro Surveill; 2019 Feb; 24(6):. PubMed ID: 30755293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and reactogenicity of acellular diphtheria/tetanus/pertussis vaccines given as a pre-school booster: effect of simultaneous administration of MMR.
    Miller E; Waight P; Laurichesse H; Andrews N; Thornton C; Sesardic D; Corbel M
    Vaccine; 2001 Jul; 19(28-29):3904-11. PubMed ID: 11427264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Immunisation Beliefs and Intentions Measure (IBIM): predicting parents' intentions to immunise preschool children.
    Tickner S; Leman PJ; Woodcock A
    Vaccine; 2010 Apr; 28(19):3350-62. PubMed ID: 20206284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.
    Omeñaca F; Garcia-Sicilia J; Boceta R; Sistiaga-Hernando A; García-Corbeira P
    Pediatr Infect Dis J; 2007 Sep; 26(9):824-9. PubMed ID: 17721379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL; Hutter GE
    Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of routine paediatric vaccines in England often deviates from the immunisation schedule.
    Bauwens J; de Lusignan S; Sherlock J; Ferreira F; Künzli N; Bonhoeffer J
    Vaccine X; 2021 Dec; 9():100115. PubMed ID: 34622200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of antibodies in 4-8 year old Austrian children after vaccination with hexavalent DTaP-HBV-IPV/Hib and MMR vaccines.
    Paulke-Korinek M; Fischmeister G; Grac A; Rendi-Wagner P; Kundi M; Mohsenzadeh-Rabbani A; Moritz K; Fenninger B; Jarisch R; Jasinska J; Holzmann H; Wiedermann U; Kollaritsch H
    Vaccine; 2011 Jul; 29(32):5130-6. PubMed ID: 21624412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
    Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
    Vaccine; 2011 Nov; 29(50):9337-44. PubMed ID: 22001281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunisation coverage in children with cerebral palsy compared with the general population.
    Greenwood VJ; Crawford NW; Walstab JE; Reddihough DS
    J Paediatr Child Health; 2013 Feb; 49(2):E137-41. PubMed ID: 23360148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
    Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
    Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.